Miranda

mgreenberg@dcat.org

LATEST

GSK Rejects Unilever’s $68-Bn Bid for its Consumer Health Biz
By

By
GlaxoSmithKline (GSK) has rejected a £50 billion ($68 billion) bid from Unilever to acquire GSK’s Consumer Healthcare business. Unilever reported on January 19, 2022 that it will not increase its…

Merck & Co.’s Head of Human Health Named as IFF CEO
By

By
Merck & Co.’s Executive Vice President (EVP) and President of Human Health, Frank Clyburn, will leave the company on February 1, 2022, to become Chief Executive Officer at IFF. Mr.…

Supplier News: Helsinn, Samsung, Piramal & More
By

By
The latest from CDMOs, CMOs, and suppliers featuring HAS Healthcare Advanced Synthesis, Lonza, Samsung Biologics, Emergent BioSolutions, Catalent, Piramal Pharma Solutions, Eurofins CDMO, Procaps, Ori Biotech, and Forge Biologics. Chemicals/Chemical…

Senate Committee Advances Nomination of New FDA Commissioner
By

By
The US Senate Committee for Health, Education, Labor, and Pensions (HELP) voted last week (January 13, 2022) to advance the nomination of Robert Califf, M.D., as Commissioner of the US…

COVID News: GSK, Novartis, Pfizer, Moderna & More
By

By
The latest on COVID-19 vaccines/drugs, manufacturing, and testing from GSK, Novartis, Pfizer, AstraZeneca, Moderna, Novavax, and BioNTech. Manufacturing and supply of COVID-19 vaccines and drugs US Gov’t To Buy More…

Supplier News: Recipharm, Catalent, SK, Avid & More
By

By
The latest from CDMOs, CMOs, and suppliers featuring Recipharm, Catalent, SK Inc./Center for Breakthrough Medicines, Avid Bioservices, RoslinCT, Cellipont Bioservices, INCOG BioPharma Services and Symbiosis Pharmaceutical Services. General Recipharm Divests…

Pfizer, Beam Therapeutics in $1.35-Bn Rare-Disease Pact
By

By
Pfizer and Beam Therapeutics, a Cambridge, Massachusetts-based bio/pharma company developing precision genetic medicines through base editing, have entered into an exclusive four-year research collaboration for rare genetic diseases in a…

M&A News: Novo Nordisk, Novartis, Sanofi & More
By

By
A roundup of mergers & acquisitions from Novo Nordisk, Novartis, Sanofi, Gilead Sciences, AbbVie, Merck KGaA, AstraZeneca, and Takeda. Novo Nordisk Completes $3.3-Bn Acquisition of DicernaLast month (December 28, 2021),…

Partnering News: Gilead, Merck & Co., Sanofi & More
By

By
A roundup of bio/pharmaceutical partnering news from: Gilead/Merck & Co.; Sanofi/Exscientia; Bayer/Mammoth Biosciences; Novartis/BeiGene; Novartis/Alnylam; BioNTech/Crescendo Biologics; AstraZeneca/Neurimmune; Lilly/Entos;Pfizer/Acuitas Therapeutics; Bristol-Myers Squibb/Evotec; Regeneron/Ultragenyx; and Eisai/Roivant. Gilead, Merck & Co. in…

Global Briefs: Lilly, Daiichi Sankyo, Merck KGaA & More
By

By
A roundup of news from Eli Lilly and Company, Daiichi Sankyo, Merck KGaA, and Blueprint Medicines. FDA OKs Lilly’s Biosimilar of Sanofi’s LantusThe US Food and Drug Administration (FDA) has…